Table 4. Expression of EMP1, EMP2, and EMP3 in invasive ductal carcinoma on the basis of subtype.
| Characteristics | HR+HER2− (n = 219) | HR+HER2+ (n = 38) | HER2 (n = 35) | TNBC (n = 126) | p-value | |
|---|---|---|---|---|---|---|
| EMP1 | 0.762 | |||||
| Negative | 7 (3.2) | 0 (0.0) | 0 (0.0) | 3 (2.4) | ||
| Positive | 212 (96.8) | 38 (100.0) | 35 (100.0) | 123 (97.6) | ||
| EMP2 | < 0.001 | |||||
| Negative | 43 (19.6) | 4 (10.5) | 8 (22.9) | 60 (47.6) | ||
| Positive | 176 (80.4) | 34 (89.5) | 27 (77.1) | 66 (52.4) | ||
| EMP3 | 0.009 | |||||
| Negative | 35 (16.0) | 1 (2.6) | 2 (5.7) | 28 (22.2) | ||
| Positive | 184 (84.0) | 37 (97.4) | 33 (94.3) | 98 (77.8) | ||
Values are presented as number (%).
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; TNBC = triple-negative breast cancer; EMP = epithelial membrane protein.